Gain Therapeutics, Inc. (Nasdaq: GANX) announced its financial results for the year ended December 31, 2025, alongside a corporate update regarding its lead drug candidate, GT-02287, which is in clinical development for Parkinson's disease. The company reported a net loss of $20.2 million, or $0.61 per share, compared to a net loss of $20.4 million, or $0.89 per share, for the previous year. Research and development expenses decreased to $10.2 million from $10.8 million, attributed to optimized pipeline costs despite unfavorable foreign exchange impacts. General and administrative expenses also saw a decline to $8.5 million from $9.6 million, primarily due to lower stock-based compensation and legal fees.

In terms of operational progress, Gain Therapeutics highlighted advancements in the clinical development of GT-02287, which targets the underlying biology of Parkinson's disease. The company is currently conducting a Phase 1b extension study, with promising results indicating stable MDS-UPDRS scores across participants after 150 days of treatment. The company aims to shift the treatment paradigm from symptomatic relief to disease modification, with further data expected to be presented at scientific conferences throughout the year.

The company also announced upcoming milestones, including the anticipated clearance of an IND submission to the FDA in the second quarter of 2026, which will facilitate the Phase 2 clinical development of GT-02287. The Phase 2 trial is expected to commence in the third quarter of 2026, with results from the Phase 1b study anticipated in the fourth quarter of 2026. Gain Therapeutics continues to engage with the FDA regarding the development of GT-02287, which has shown potential in both idiopathic and GBA1 Parkinson's disease.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.